Clinical Trials
8
Active:1
Completed:4
Trial Phases
3 Phases
Phase 1:1
Phase 2:3
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (50.0%)Phase 2
3 (37.5%)Phase 1
1 (12.5%)To Evaluate the Effect of MCS® in Prostate Cancer Prevention
Phase 2
Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: PlaceboDrug: MCS®
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Target Recruit Count
- 702
- Registration Number
- NCT02042807
- Locations
- 🇨🇳
Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia
Phase 2
Terminated
- Conditions
- Male Oligoasthenospermia
- Interventions
- Drug: MCS
- First Posted Date
- 2009-11-19
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Target Recruit Count
- 3
- Registration Number
- NCT01016340
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Pharmacokinetics of MCS in Healthy Volunteers
Phase 1
- Conditions
- Healthy
- Interventions
- Drug: MCS-2 soft-gel capsule
- First Posted Date
- 2009-10-28
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT01003171
MCS in the Treatment of Lower Urinary Tract Symptoms
Phase 2
Completed
- Conditions
- Lower Urinary Tract SymptomsBenign Prostatic Hyperplasia
- Interventions
- Drug: MCS-2 15 mg/dayDrug: PlaceboDrug: MCS-2 30 mg/day
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Target Recruit Count
- 274
- Registration Number
- NCT01002417
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms
Phase 3
Completed
- Conditions
- Lower Urinary Tract SymptomsBenign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT01002274
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
- Prev
- 1
- 2
- Next
News
No news found